Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Moderna Inc
(NQ:
MRNA
)
77.40
-0.19 (-0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
April 22, 2024
Via
ACCESSWIRE
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
April 17, 2024
Via
ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Leading the Way in Tuesday Trading Based on Percentage Gain
April 09, 2024
Via
Investor Brand Network
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
April 03, 2024
Via
ACCESSWIRE
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
March 27, 2024
Via
ACCESSWIRE
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
March 26, 2024
Via
ACCESSWIRE
Moderna to Present at Upcoming Investor Conferences in March 2024
February 28, 2024
Via
ACCESSWIRE
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
February 22, 2024
Via
ACCESSWIRE
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
Via
ACCESSWIRE
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
February 29, 2024
Via
ACCESSWIRE
Novavax’s dispute resolution and upcoming earnings call
February 23, 2024
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.
Via
MarketBeat
Topics
Earnings
Exposures
COVID-19
Financial
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
February 06, 2024
Via
ACCESSWIRE
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
February 01, 2024
Via
ACCESSWIRE
Moderna Named to Fortune's List of World's Most Admired Companies
January 31, 2024
Via
ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
January 02, 2024
Via
Investor Brand Network
Moderna to Present at Upcoming Conferences in November 2023
November 08, 2023
Via
ACCESSWIRE
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
November 08, 2023
Via
ACCESSWIRE
3 health care stocks off to strong starts in 2024
January 10, 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Are defensive sectors ready to outshine growth in 2024?
January 06, 2024
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.
Via
MarketBeat
MarketBeat Week in Review – 1/1 - 1/5
January 06, 2024
Stocks finished the week looking for direction after a hotter-than-expected Jobs report and as investors wait for inflation information and big bank earnings
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
3 reasons 2024 Moderna shareholders may party like it's 2021
January 05, 2024
With interest in Moderna Inc. stock picking up alongside news flow, investors could be in for some very healthy 2024 gains.
Via
MarketBeat
Exposures
COVID-19
Pfizer's chaotic year wraps up with plunging stock, grim guidance
December 21, 2023
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets.
Via
MarketBeat
Exposures
COVID-19
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
Via
ACCESSWIRE
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
December 14, 2023
Via
ACCESSWIRE
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
December 14, 2023
Via
ACCESSWIRE
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
December 12, 2023
Via
ACCESSWIRE
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
December 07, 2023
Via
ACCESSWIRE
Upwork underscores the strength of the AI gig economy
November 28, 2023
Upwork has been pursuing its goal of being the world's preeminent destination for artificial intelligence (AI) related talent and freelancers
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
November 14, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.